UK Study Assessing Flexible Dose Fesoterodine in Adults

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To explore the effects of fesoterodine when used in a flexible dose manner

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fesoterodine

Criteria

Inclusion Criteria:

• Male or female >18 years old

• OAB for >3 months

Exclusion Criteria:

• Patients with conditions that would contraindicate for fesoterodine use

• Patients with significant hepatic and renal disease or other significant unstable diseases.

• OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.